210 related articles for article (PubMed ID: 33499698)
1. Intravitreal aflibercept partially reverses severe non-proliferative diabetic retinopathy in treatment-naïve patients.
Tao Y; Jiang P; Liu M; Liu Y; Song L; Wang H
J Int Med Res; 2021 Jan; 49(1):300060520985369. PubMed ID: 33499698
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2021 May; 31(3):1201-1207. PubMed ID: 32429690
[TBL] [Abstract][Full Text] [Related]
3. Functional and anatomic results of up to 24 months aflibercept treatment for diabetic macular edema in real-life setting.
Tsapardoni FN; Makri OE; Lagogiannis AP; Tsekouras IK; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD
Hell J Nucl Med; 2019; 22 Suppl 2():47-54. PubMed ID: 31802045
[TBL] [Abstract][Full Text] [Related]
4. Aflibercept 5+PRN with retinal laser photocoagulation is more effective than retinal laser photocoagulation alone and aflibercept 3+PRN with retinal laser photocoagulation in patients with high-risk proliferative diabetic retinopathy and diabetic macular edema: a 12-month clinical trial.
Li S; Tao Y; Yang M; Zhao H; Si M; Cui W; Wang H
Front Endocrinol (Lausanne); 2024; 15():1286736. PubMed ID: 38455651
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
Chen YY; Chang PY; Wang JK
Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
[TBL] [Abstract][Full Text] [Related]
6. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study.
Garweg JG; Stefanickova J; Hoyng C; Schmelter T; Niesen T; Sowade O; Sivaprasad S;
Ophthalmol Retina; 2019 Jul; 3(7):567-575. PubMed ID: 31080168
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
Glassman AR; Baker CW; Beaulieu WT; Bressler NM; Punjabi OS; Stockdale CR; Wykoff CC; Jampol LM; Sun JK;
JAMA Ophthalmol; 2020 Apr; 138(4):341-349. PubMed ID: 32077907
[TBL] [Abstract][Full Text] [Related]
8. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
Bahrami B; Hong T; Schlub TE; Chang AA
Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
[TBL] [Abstract][Full Text] [Related]
9. A Comparison Study of Ranibizumab and Aflibercept in Patients with Naive Diabetic Macular Edema in Presence of Serous Retinal Detachment.
Kaldırım H; Yazgan S; Kırgız A; Atalay K; Savur F
Curr Eye Res; 2019 Sep; 44(9):987-993. PubMed ID: 30983426
[No Abstract] [Full Text] [Related]
10. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: A Pilot Study.
Andrade GC; Dias JR; Maia A; Farah ME; Meyer CH; Rodrigues EB
Retina; 2016 Sep; 36(9):1640-5. PubMed ID: 26991646
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice.
Plaza-Ramos P; Borque E; García-Layana A
PLoS One; 2019; 14(10):e0223793. PubMed ID: 31644594
[TBL] [Abstract][Full Text] [Related]
12. Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.
Yoshimoto M; Takeda N; Yoshimoto T; Matsumoto S
J Med Case Rep; 2021 Jul; 15(1):403. PubMed ID: 34311786
[TBL] [Abstract][Full Text] [Related]
13. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
14. [Ranibizumab and aflibercept for diabetic macular edema-retrospective study with real-life data after 12 months].
Holbach B; Zeman F; Helbig H; Gamulescu MA
Ophthalmologe; 2020 Jul; 117(7):687-692. PubMed ID: 31705192
[TBL] [Abstract][Full Text] [Related]
15. THE EFFECT OF AGE ON AFLIBERCEPT (EYLEA) RESPONSE IN DIABETIC MACULAR EDEMA.
Ozsaygili C; Duru Z; Cicek A; Ulusoy DM; Demirtas AA; Duru N
Retina; 2020 Jun; 40(6):1038-1043. PubMed ID: 30897067
[TBL] [Abstract][Full Text] [Related]
16. Retinal Microvasculature and Visual Acuity after Intravitreal Aflibercept in Diabetic Macular Edema: An Optical Coherence Tomography Angiography Study.
Busch C; Wakabayashi T; Sato T; Fukushima Y; Hara C; Shiraki N; Winegarner A; Nishida K; Sakaguchi H; Nishida K
Sci Rep; 2019 Feb; 9(1):1561. PubMed ID: 30733512
[TBL] [Abstract][Full Text] [Related]
17. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
18. Three versus five intravitreal aflibercept injections as the initial loading phase in the treatment of diabetic macular edema: one-year results.
Cakir A; Erden B; Bolukbasi S; Sever O; Erkul SO; Osmanbasoglu OA; Karaca G; Elcioglu MN
Arq Bras Oftalmol; 2020; 83(5):396-401. PubMed ID: 33084817
[TBL] [Abstract][Full Text] [Related]
19. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal aflibercept for diabetic macular edema.
Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
